| Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma G Roex, M Timmers, K Wouters, D Campillo-Davo, D Flumens, ... Journal of Hematology & Oncology 13 (1), 1-14, 2020 | 130 | 2020 |
| Chimeric antigen receptor-modified T cell therapy in multiple myeloma: beyond B cell maturation antigen M Timmers, G Roex, Y Wang, D Campillo-Davo, VFI Van Tendeloo, Y Chu, ... Frontiers in immunology 10, 1613, 2019 | 90 | 2019 |
| Dendritic cell-based immunotherapy of acute myeloid leukemia HH Van Acker, M Versteven, FS Lichtenegger, G Roex, D Campillo-Davo, ... Journal of Clinical Medicine 8 (5), 579, 2019 | 68 | 2019 |
| The quest for the best: How TCR affinity, avidity, and functional avidity affect TCR-engineered T-cell antitumor responses D Campillo-Davo, D Flumens, E Lion Cells 9 (7), 1720, 2020 | 67 | 2020 |
| The antihypertensive drug hydralazine activates the intrinsic pathway of apoptosis and causes DNA damage in leukemic T cells MJ Ruiz-Magaña, R Martínez-Aguilar, E Lucendo, D Campillo-Davo, ... Oncotarget 7 (16), 21875, 2016 | 49 | 2016 |
| Influence of TYK2 in systemic sclerosis susceptibility: a new locus in the IL-12 pathway E López-Isac, D Campillo-Davo, L Bossini-Castillo, SG Guerra, S Assassi, ... Annals of the rheumatic diseases 75 (8), 1521-1526, 2016 | 47 | 2016 |
| Influence of TYK2 in systemic sclerosis susceptibility: a new locus in the IL-12 pathway. E Lopez-Isac, D Campillo-Davo, L Bossini-Castillo, SG Guerra, S Assassi, ... 1468-2060, 2015 | 47 | 2015 |
| MRGPRX2 and immediate drug hypersensitivity: Insights from cultured human mast cells J Elst, V Sabato, MA Faber, CH Bridts, C Mertens, M Van Houdt, ... Journal of Investigational Allergology and Clinical Immunology 31 (6), 489-499, 2021 | 43 | 2021 |
| Novel insights on MRGPRX2-mediated hypersensitivity to neuromuscular blocking agents and fluoroquinolones J Elst, M Maurer, V Sabato, MA Faber, CH Bridts, C Mertens, M Van Houdt, ... Frontiers in Immunology 12, 2021 | 38 | 2021 |
| Efficient and non-genotoxic RNA-based engineering of human T cells using tumor-specific T cell receptors with minimal TCR mispairing D Campillo-Davo, F Fujiki, JMJ Van den Bergh, H De Reu, ELJM Smits, ... Frontiers in Immunology 9, 2503, 2018 | 36 | 2018 |
| Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells G Roex, D Campillo-Davo, D Flumens, PAG Shaw, L Krekelbergh, ... Journal of Translational Medicine 20 (1), 1-13, 2022 | 32 | 2022 |
| The ins and outs of messenger RNA electroporation for physical gene delivery in immune cell-based therapy D Campillo-Davo, M De Laere, G Roex, M Versteven, D Flumens, ... Pharmaceutics 13 (3), 396, 2021 | 29 | 2021 |
| A versatile T cell-based assay to assess therapeutic antigen-specific PD-1-targeted approaches M Versteven, JMJ Van den Bergh, K Broos, F Fujiki, D Campillo-Davo, ... Oncotarget 9 (45), 27797, 2018 | 29 | 2018 |
| An MIF promoter polymorphism is associated with susceptibility to pulmonary arterial hypertension in diffuse cutaneous systemic sclerosis L Bossini-Castillo, D Campillo-Davó, E López-Isac, FD Carmona, ... The Journal of Rheumatology 44 (10), 1453-1457, 2017 | 28 | 2017 |
| The role of the common gamma-chain family cytokines in γδ T cell-based anti-cancer immunotherapy HH Van Acker, D Campillo-Davo, G Roex, M Versteven, EL Smits, ... Cytokine & Growth Factor Reviews 41, 54-64, 2018 | 25 | 2018 |
| Cellular immunotherapy: a clinical state-of-the-art of a new paradigm for cancer treatment ÁR Pérez, D Campillo-Davo, VFI Van Tendeloo, D Benítez-Ribas Clinical and Translational Oncology 22, 1923–1937, 2020 | 21 | 2020 |
| Rapid assessment of functional avidity of tumor-specific T cell receptors using an antigen-presenting tumor cell line electroporated with full-length tumor antigen mRNA D Campillo-Davo, M Versteven, G Roex, H De Reu, S van der Heijden, ... Cancers 12 (2), 256, 2020 | 16 | 2020 |
| PD-L1 siRNA-mediated silencing in acute myeloid leukemia enhances anti-leukemic T cell reactivity D van Ens, CM Mousset, TJA Hutten, AB van der Waart, D Campillo-Davo, ... Bone Marrow Transplantation 55 (12), 2308-2318, 2020 | 14 | 2020 |
| Engineering of regulatory T cells by means of mRNA electroporation in a GMP-compliant manner I Janssens, DC Davó, J Van den Bos, H De Reu, ZN Berneman, I Wens, ... Cytotherapy 24 (6), 659-672, 2022 | 7 | 2022 |
| Trial Watch: Adoptive TCR-Engineered T-Cell Immunotherapy for Acute Myeloid Leukemia D Campillo-Davo, S Anguille, E Lion Cancers 13 (18), 4519, 2021 | 6 | 2021 |
